WolffAC, HammondMEH, AllisonKH, et al.Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol2018;36:2105–2122.
WolffAC, HammondMEH, AllisonKH, Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 2018;36:2105–2122.10.1200/JCO.2018.77.8738)| false
GradisharWJ, AndersonBO, AbrahamJ, et al.NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2021. Accessed April 23, 2021. To view the most recent version, visit NCCN.org
GradisharWJ, AndersonBO, AbrahamJ, NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2021. Accessed April 23, 2021. To view the most recent version, visit NCCN.org)| false
PressMF, SauterG, BuyseM, et al.HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists Guidelines with FISH scores used for enrollment in breast cancer international research group clinical trials. J Clin Oncol2016;34:3518–3528.
PressMF, SauterG, BuyseM, HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists Guidelines with FISH scores used for enrollment in breast cancer international research group clinical trials. J Clin Oncol 2016;34:3518–3528.10.1200/JCO.2016.66.6693)| false
PressMF, VillalobosI, SantiagoA, et al.Assessing the new American Society of Clinical Oncology/College of American Pathologists guidelines for HER2 testing by fluorescence in situ hybridization: experience of an academic consultation practice. Arch Pathol Lab Med2016;140:1250–1258.
PressMF, VillalobosI, SantiagoA, Assessing the new American Society of Clinical Oncology/College of American Pathologists guidelines for HER2 testing by fluorescence in situ hybridization: experience of an academic consultation practice. Arch Pathol Lab Med 2016;140:1250–1258.10.5858/arpa.2016-0009-OA)| false
BallardM, JalikisF, KringsG, ‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study. Mod Pathol 2017;30:227–235.2773944010.1038/modpathol.2016.175)| false
JohnstonSRD, HeggR, ImSA, et al.Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal woman with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. J Clin Oncol2021;39:79–89.
JohnstonSRD, HeggR, ImSA, Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal woman with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. J Clin Oncol 2021;39:79–89.32822287)| false